Please login to the form below
lenvatinib
This page shows the latest lenvatinib news and features for those working in and with pharma, biotech and healthcare.
Merck’s Keytruda receives FDA approval for advanced endometrial cancer
The drug has also been approved in combination with Lenvima (lenvatinib) to treat patients with advanced endometrial carcinoma.
Latest news
-
Merck and Eisai share crucial phase 3 trial results for advanced endometrial carcinoma treatment
The crucial study assessed the combination of Lenvima (lenvatinib) – a multiple receptor tyrosine kinase inhibitor administered orally as a pill, discovered by Eisai – with Merck’s anti-PD-1 therapy Keytruda ... Merck and Eisai are evaluating the
-
Merck, Eisai’s Keytruda/Lenvima regimen scores full approval in endometrial cancer
The US Food and Drug Administration (FDA) has cleared checkpoint inhibitor Keytruda (pembrolizumab) plus tyrosine kinase inhibitor (TKI) Lenvima (lenvatinib) for the treatment of patients with advanced endometrial cancer that is
-
Merck & Co announces results at ASCO for Keytruda plus Lenvima for kidney cancer patients
The new data, presented at the 2021 American Society of Clinical Oncology ( ASCO) annual meeting, comes from the CLEAR/KEYNOTE-581 study, which is evaluating Lenvima (lenvatinib) plus Keytruda (pembrolizumab) or
-
New survival data for Merck, Eisai’s Keytruda/Lenvima combination shows promise in kidney cancer
In this study, checkpoint inhibitor Keytruda (pembrolizumab) plus Lenvima (lenvatinib) and Lenvima plus everolimus were compared to Pfizer’s tyrosine kinase inhibitor (TKI) Sutent (sunitinib) for the first-line treatment of
-
Merck, Eisai’s Keytruda plus Lenvima combo hits the mark in renal cancer
The results, from the KEYNOTE-581/CLEAR trial, demonstrated that Keytruda (pembrolizumab) and Lenvima (lenvatinib) met the primary endpoint of improved progression-free survival (PFS) compared to Pfizer’s Sutent (sunitinib)
More from news
Approximately 2 fully matching, plus 24 partially matching documents found.
Latest Intelligence
-
Eisai: Bucking the trend with R&D growth
The monoclonal antibody farletuzumab is in phase III trials for ovarian cancer, and has reached the phase II stage for non-small cell lung cancer, while lenvatinib is also in phase
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Country Manager, Healthcare Communications Agency, Germany
-
Highly competitive salary
- bluebird bio reveals plans to launch two gene therapies
- Sanofi halts recruitment for trials assessing MS treatment
- Eli Lilly to make bebtelovimab commercially available to US states from August
- The patient voice – the value of patient-reported outcomes in HTA
- AbbVie and Sosei Heptares collaborate in new agreement worth up to $1.2bn
- ONS records a continued fall in UK COVID-19 infections
- Powering Rapid Cognitive Analysis with AI
- How the Royal Society’s EiR programme can help to drive UK innovation
- BMS and 2seventy bio announce positive results for multiple myeloma treatment
- Roche and Cend Therapeutics to evaluate pancreatic cancer combination therapy
- Aqilion initiates phase 1 clinical trial for chronic inflammatory diseases
- JCVI publishes statement on London polio vaccination strategy
- Eli Lilly to make bebtelovimab commercially available to US states from August
- Amgen acquires ChemoCentryx in $3.7bn cash deal
- AstraZeneca’s Alexion agrees on $775m settlement with Chugai for Ultomiris
- EMA backs adjuvant use of Roche’s breast cancer ADC Kadcyla
- FDA approves Coherus’ Cimerli as biosimilar interchangeable with Lucentis for all five indications
- Gilead Sciences set to acquire MiroBio in deal worth over $400m
PMHub
Aptus Health
Aptus Health is dedicated to advancing health engagement. The company offers end-to-end digital health engagement solutions spanning all areas of...
